The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Implementing flexible and adapted follow-up strategies in a patient-centric, phase II trial of first-line lorlatinib for advanced ALK-positive non–small cell lung cancer (CTONG2203).
 
Jia-Xin Lin
No Relationships to Disclose
 
Qing Zhou
No Relationships to Disclose
 
Hong-Hong Yan
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Guowu Wu
No Relationships to Disclose
 
Anwen Liu
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Ying Liu
No Relationships to Disclose
 
Haipeng Xu
No Relationships to Disclose
 
Yingying Du
No Relationships to Disclose
 
Yi Yang
No Relationships to Disclose
 
Hai-Yan Tu
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Si-Yang Liu
No Relationships to Disclose